about
Advances in the treatment of relapsed or refractory Hodgkin's lymphomaHodgkin's lymphoma therapy: past, present, and future.Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's LymphomaImproving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.Current role of FDG PET/CT in lymphoma.Role of PET in lymphoma.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?Methylation of miR124a-1, miR124a-2, and miR124a-3 in Hodgkin lymphoma.Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation.Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.MET and MST1R as prognostic factors for classical Hodgkin's lymphoma.Pathobiology of hodgkin lymphoma
P2860
Q27694504-53E09942-F1BA-4054-AE5C-46AA4B6390D2Q34296914-74CC9050-4E6B-4107-9CA2-0ABF9D9AE0A6Q35158345-B48DF1CF-D765-4E9E-BFA2-AF56D2DDA0CBQ35556061-9EC5EFBA-5B5E-4121-8EF9-61CE27D51623Q35691210-ABE15C28-EC19-402A-B839-0D7520698F06Q36816955-3C38A90B-3E66-42B0-A7B5-72E3081907A4Q37144956-1B608FDB-0A8F-4184-9848-B55568838934Q37529430-338C3DB1-E293-42EB-B0E9-D2C23A2B5DEAQ37649035-72D8D4A1-7CC0-40AC-9D33-2A62BD46B89DQ38187365-7C003D46-0395-4C95-AC99-D597CECDDC95Q38195220-50D0331B-D81E-48FB-BED5-72FC94A37A5AQ38476250-45948973-9481-4D36-95A2-A0C05D95CF65Q38607549-B1594681-91E7-46B0-A80D-870172D4C7B4Q42315418-0EACF26E-1EF7-4A27-BA1A-D6AAED362858Q43188726-0B3949FE-A4B1-4983-8773-14499338C3D9Q46864071-A18CAF94-4AAA-4C68-8449-4F83CCFFD6AAQ50600769-5AA5F8BB-4838-45A3-9616-99481210FE1DQ51395861-953C461B-FE59-4D0F-9EA7-8AFE004C02C2Q53245652-0A1604B7-F565-420F-B163-1DC92F66F1BFQ54439373-649690EA-70B0-4030-8ECF-CE78F6B8700FQ56986903-7503F1BD-BFFA-472C-9754-34FE780A28E3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Salvage therapy for Hodgkin's lymphoma.
@en
Salvage therapy for Hodgkin's lymphoma.
@nl
type
label
Salvage therapy for Hodgkin's lymphoma.
@en
Salvage therapy for Hodgkin's lymphoma.
@nl
prefLabel
Salvage therapy for Hodgkin's lymphoma.
@en
Salvage therapy for Hodgkin's lymphoma.
@nl
P1433
P1476
Salvage therapy for Hodgkin's lymphoma.
@en
P2093
Fahd Quddus
P304
P356
10.1097/PPO.0B013E3181A1438A
P577
2009-03-01T00:00:00Z